Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells.
Interactions between CD40 and CD40 ligand (CD154) are essential in the regulation of both humoral and cellular immune responses. Forced expression of human CD154 in B chronic lymphocytic leukemia (B-CLL) cells can upregulate costimulatory and adhesion molecules and restore antigen-presenting capacity. Unfortunately, B-CLL cells are resistant to direct gene manipulation with most currently available gene transfer systems. In this report, we describe the use of a nonviral, clinical-grade, electroporation-based gene delivery system and a standard plasmid carrying CD154 cDNA, which achieved efficient (64+/-15%) and rapid (within 3 h) transfection of primary B-CLL cells. Consistent results were obtained from multiple human donors. Transfection of CD154 was functional in that it led to upregulated expression of CD80, CD86, ICAM-I and MHC class II (HLA-DR) on the B-CLL cells and induction of allogeneic immune responses in MLR assays. Furthermore, sustained transgene expression was demonstrated in long-term cryopreserved transfected cells. This simple and rapid gene delivery technology has been validated under the current Good Manufacturing Practice conditions, and multiple doses of CD154-expressing cells were prepared for CLL patients from one DNA transfection. Vaccination strategies using autologous tumor cells manipulated ex vivo for patients with B-CLL and perhaps with other hematopoietic malignancies could be practically implemented using this rapid and efficient nonviral gene delivery system.
Li
L H
LH
MaxCyte, Inc., Gaithersburg, Maryland, USA.
Biagi
E
E
Allen
C
C
Shivakumar
R
R
Weiss
J M
JM
Feller
S
S
Yvon
E
E
Fratantoni
J C
JC
Liu
L N
LN
D023201:CD40 Ligand / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use*; D018274:Electroporation / Q000379:methods; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy*; D010957:Plasmids / Q000235:genetics; D014162:Transfection / Q000379:methods*; D019076:Transgenes / Q000235:genetics
D023201:CD40 Ligand